Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146815 | 1.00 | IDO1 (0.50) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL146814 | 1.00 | IDO1 (0.50) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL18483667 | 0.95 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL29979241 | 0.95 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL144290 | 0.95 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL144289 | 0.95 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL146598 | 0.91 | IDO1 (0.50) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL146597 | 0.91 | IDO1 (0.50) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL19465717 | 0.91 | IDO1 (0.50) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL15444352 | 0.88 | IDO1 (0.45) | IDO1CYP3A4CYP2C9TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2824100-B1 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORP (US) | 2018-02-21 | — | — | EP | claimed |
| EP-2315756-B9 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2015-07-22 | — | — | EP | claimed |
| EP-2315756-B1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2014-09-03 | — | — | EP | claimed |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210030722-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-10653677-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190298700-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| US-10369137-B2 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2019-08-06 | — | — | US | disclosed |
| US-10034939-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | THE UNIVERSITY OF CHICAGO (US) | 2018-07-31 | — | — | US | disclosed |
| US-10034864-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180177769-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20170348289-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-9789094-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030722-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-10369137-B2 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-10653677-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-10034864-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20190298700-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20170348289-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | ICOS, CD274, IDO1 | IDO1 3/4885CYP3A4 2311/4885CYP2C9 4210/4885 |
| US-10034939-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | ICOS, CD274, IDO1 | IDO1 3/4885CYP3A4 2311/4885CYP2C9 4210/4885 |
| US-20180177769-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.